Business

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

Financial Post · September 24, 2026 at 7:06 a.m.

TORONTO and HOUSTON, Sept.

24, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting can

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

More from Financial Post

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

EasyPark Receives Three Awards at Canadian Parking Association Conference

More in Business

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

EasyPark Receives Three Awards at Canadian Parking Association Conference

Hitachi Joins Anthropic’s Critical Infrastructure Defense Program

Gold Reserve Files Response in Citgo Appeal, Supporting Venezuela’s Request for Abeyance, Subject to Support of the United States